Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TPST | US
0
0%
Healthcare
Biotechnology
30/06/2024
08/04/2026
1.56
1.60
1.60
1.54
Tempest Therapeutics Inc. a clinical-stage oncology company develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495 a dual antagonist of EP2 and EP4 receptors of prostaglandin E2 which is in a Phase 1 trial to treat solid tumors; and TPST-1120 a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1 a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics Inc. is headquartered in Brisbane California.
View LessValue Stock (Price to Book < 3)
Negative Momentum (Declining Price)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
High Debt to Equity (> 0.75)
High Debt to Asset (> 0.45)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
83.2%1 month
92.9%3 months
79.8%6 months
112.2%-
-
1.71
1.20
0.48
0.31
-
-
-31.25M
39.32M
39.32M
-
-
-
-
-289.26
5.12
8.91
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.45
Range1M
0.97
Range3M
1.65
Rel. volume
0.79
Price X volume
236.02K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CIBUS GLOBAL LTD. | CBUS | Biotechnology | 1.465 | 43.20M | -7.86% | n/a | 81.33% |
| Werewolf Therapeutics Inc. Common Stock | HOWL | Biotechnology | 0.9844 | 43.02M | -1.56% | n/a | 35.26% |
| Entera Bio Ltd | ENTX | Biotechnology | 1.17 | 42.50M | 0.00% | n/a | 3.91% |
| Caladrius Biosciences Inc | LSTA | Biotechnology | 5 | 41.60M | 0.00% | n/a | 0.58% |
| Minerva Neurosciences Inc | NERV | Biotechnology | 5.42 | 37.90M | 4.63% | n/a | -194.60% |
| PDS Biotechnology Corporation | PDSB | Biotechnology | 0.99 | 36.45M | 7.84% | n/a | 78.85% |
| Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.17 | 36.45M | 0.00% | n/a | 4.22% |
| SciSparc Ltd. Ordinary Shares | SPRC | Biotechnology | 3.42 | 35.42M | 3.01% | n/a | 1.00% |
| Cognition Therapeutics Inc. Common Stock | CGTX | Biotechnology | 0.8802 | 35.33M | 7.68% | n/a | 2.71% |
| SABS | SABS | Biotechnology | 3.73 | 34.43M | -0.80% | n/a | 11.58% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.21 | 17.68M | 4.31% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6564 | 12.68M | 0.37% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 5.67 | 8.64M | 80.57% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.264 | 3.23M | 2.35% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2692 | 2.56M | 21.37% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.02 | 1.11M | -0.98% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.31 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.71 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 79.80 | - | Par |
| Debt to Equity | 1.20 | -1.23 | Expensive |
| Debt to Assets | 0.48 | 0.25 | Expensive |
| Market Cap | 39.32M | - | Emerging |